8-K filing — iBio, Inc. (IBIO)
Filed: 2026-08-28 AccNo: 0001420720-26-000019 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio, a clinical-stage biotechnology company, announced fiscal year 2026 results marking its transition to clinical development with initiation of Phase 1 trials for IBIO-600, a long-acting anti-myostatin antibody. The company advanced IBIO-610 into IND-enabling studies showing fat-selective weight loss potential and completed successful financings totaling $126 million, extending cash runway into fiscal 2028. R&D expenses increased to $19.6 million from $8.3 million year-over-year, while the company held $88 million in cash and investments.
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5